<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04434456</url>
  </required_header>
  <id_info>
    <org_study_id>C-HEAL</org_study_id>
    <nct_id>NCT04434456</nct_id>
  </id_info>
  <brief_title>Carotid Artery Aneurysm Treatment Using CGuard Divert-And-Heal Strategy</brief_title>
  <acronym>C-HEAL</acronym>
  <official_title>Prospective Observational Study of CGuard MicroNet Covered Stent System Use as a Flow Diverter in the Endovascular Exclusion of Carotid Artery Aneurysms. (CGuard Divert-and-HEAL C-HEAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Piotr Musialek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>John Paul II Hospital, Krakow</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-randomized, single arm, open label, academic observational study of CGuard MicroNet
      covered stent system use to achieve endovascular lumen reconstruction in carotid artery
      aneurysms with indications for treatment (enlarging and/or dissecting / symptomatic).

      Jagiellonian University Medical College research project.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carotid artery aneurysm (CAA) is a relatively infrequent, but significant clinical condition
      with numerous diagnostic and therapeutic implications. CAA affects laminal flow in the
      carotid artery implicating the risk of thrombus formation in the aneurysm cavity, and
      subsequent ischemic stroke from distal embolization. Another important clinical problem
      related to the CAA is a possible aneurysm dissection and rupture. Symptomatic CAA and
      increasing dimensions of CAA institute unquestioned indications for the CAA treatment.

      Surgical carotid aneurysm repair bears a significant risk (periprocedural stroke, cranial
      nerve damage, carotid artery ligation). Therefore endovascular techniques of CAA exclusion
      were developed. Covered stents, stent-grafts, and combined stenting and aneurysm embolization
      with coils were applied. However, covered stents were demonstrated to increase the restenosis
      risk, and other complications such as CAA neck endo-leak.

      Newer technique involves the flow diversion by implantation of stent in dense-structured
      stent (such as Wallstent) or stent-in-stent implantation. In this case a luminary flow
      dominates over aneurysm filling, which is limited by stent structure. Gradual thrombosis and
      occlusion of aneurysm cavity and healing of aneurysm follows.This method disadvantage was
      related to necessity of double stent load and increased restenosis risk (double metal layer).

      These issues were addressed only recently by the double layer mesh stents that demonstrate
      natural flow diverting capabilities. CGuard Stent system is a self-expandable stent covered
      with PET mesh (MicroNet) that prevents plaque protrusion into the vessel lumen. In addition,
      in low flow conditions MicroNet can act as the flow diverter. These stents are routinely
      implanted in elevated risk plaques in high reference centers in Europe.

      Several published observations indicate the CGuard stent also demonstrates flow-diverting
      capabilities, but the systematic observation of such application was not performed.

      C-HEAL is a non-randomized, single arm, open label academic observational study of CGuard
      stent implantation in carotid arteries in patients with symptomatic, dissecting or enlarging
      carotid artery aneurysm. Procedures are performed according to the center routine, with
      application of proximal or distal embolic protection device (if feasible), and standard
      pharmacotherapy according to the current guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of successful aneurysm exclusion</measure>
    <time_frame>6 months</time_frame>
    <description>Successful aneurysm cavity exclusion and endovascular lumen reconstruction on routine, non-invasive CT angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of procedural success</measure>
    <time_frame>Peri-procedural</time_frame>
    <description>Procedural success defined as: Technical success (successful MicroNet covered stent delivery and implantation with complete aneurysm necks coverage) and Clinical success (no complications)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of In-hospital MACNE (major adverse cardiac and neurological events)</measure>
    <time_frame>48 hrs or until discharge</time_frame>
    <description>In-hospital MACNE (death, stroke, myocardial infarction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACNE at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>MACNE at 30 days (death, stroke, myocardial infarction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of peri-procedural complications</measure>
    <time_frame>48 hrs or until discharge</time_frame>
    <description>Any complications occurring up to 48 hours post procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical efficacy at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical efficacy defined as successful aneurysm exclusion and no procedure related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical efficacy at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical efficacy defined as successful aneurysm exclusion and no procedure related complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in the target vessel segment</measure>
    <time_frame>6 months</time_frame>
    <description>Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in ultrasound evaluation of target vessel segment (if amenable to duplex Doppler examination)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in target vessel segment</measure>
    <time_frame>12 months</time_frame>
    <description>Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in ultrasound evaluation of target vessel segment (if amenable to duplex Doppler examination)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in target vessel segment</measure>
    <time_frame>24 months</time_frame>
    <description>Peak Systolic Velocity (PSV) and End Diastolic Velocity (EDV) in ultrasound evaluation of target vessel segment (if amenable to duplex Doppler examination)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Carotid Artery Aneurysm</condition>
  <arm_group>
    <arm_group_label>CGuard stenting (interventional)</arm_group_label>
    <description>CGuard implantation in the carotid artery with aneurysm requiring intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CGuard stent implantation</intervention_name>
    <description>CGuard stent implantation in the carotid artery with symptomatic, dissecting or enlarging aneurysm</description>
    <arm_group_label>CGuard stenting (interventional)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        10 to 25 patients meeting inclusion and exclusion criteria and evaluated by Vascular Team
        to receive an endovascular treatment for carotid artery aneurysm
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        General

        Inclusion Criteria:

          -  Patients older than 18 years, eligible for endovascular carotid artery aneurysm
             treatment with Micronet covered stent per Vascular Team evaluation, according to local
             standards

          -  Written, informed consent to participate

          -  Agreement to attend protocol required (standard) follow up visits and examinations

        Exclusion Criteria:

          -  Preferred treatment other than stenting (surgery or conservative treatment /
             observation) per Vascular Team evaluation

          -  Life expectancy &lt;1 year (e.g. active neoplastic disease).

          -  Chronic kidney disease with creatinine &gt; 3.0 mg/dL.

          -  Myocardial infarction in 72 hours proceeding the stenting procedure (if possible,
             postponing the procedure)

          -  Pregnancy (positive pregnancy test)

          -  Coagulopathy.

          -  History of uncontrolled contrast media intolerance

        Angiographic

        Inclusion Criteria:

          -  Carotid artery aneurysm confirmed on angiography - symptomatic, dissected or enlarging

          -  Aneurysm eligible for endovascular treatment per Vascular Team evaluation (according
             to current standards, guidelines and study center practice)

        Exclusion Criteria:

          -  Unsuccessful true lumen engagement

          -  Aneurysm neck anatomy precluding healthy-to-healthy coverage with stent

          -  Anatomic variants precluding stent implantation

          -  Mobile (free-floating) plaque elements in aorta or arteries proximal to target lesion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Musialek, MD, DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>The John Paul II Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Piotr Musialek, MD, DPhil</last_name>
    <phone>+48126142287</phone>
    <email>p.musialek@szpitaljp2.krakow.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiac and Vascular Diseases, The John Paul II Hospital</name>
      <address>
        <city>Krak√≥w</city>
        <state>Maloplska</state>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Musialek, Prof</last_name>
      <phone>+48126142287</phone>
      <email>p.musialek@szpitaljp2.krakow.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 14, 2020</last_update_submitted>
  <last_update_submitted_qc>June 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>John Paul II Hospital, Krakow</investigator_affiliation>
    <investigator_full_name>Piotr Musialek</investigator_full_name>
    <investigator_title>Jagiellonian University Professor of Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

